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Direct-To-Consumer Advertising of Prescription Drugs
Abstract
In 2007, the pharmaceutical industry spent more than $4.9 billion on direct-to-consumer advertising
(DTCA) of prescription drugs in the U.S. Controversy over DTCA has grown since the Food and Drug
Administration liberalized its regulations in 1997. Proponents claim that such advertising educates
consumers, promotes patient participation in clinical decisions, and improves patient adherence to
medication instructions. Opponents argue that such advertising is meant to persuade, not educate, and that it
promotes inappropriate use of prescription drugs, or diverts consumers from better alternatives. This Issue
Brief summarizes the evidence about the effects of DTCA, and proposes guidelines for improving the utility
of prescription drug advertising.
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Only the U.S. and New Zealand permit direct marketing of prescription drugs to 
consumers. The Food and Drug Administration (FDA) acquired jurisdiction over 
DTCA of prescription drugs in 1962. For the next 35 years, television advertising 
was limited by the requirement that ads summarize potential adverse reactions and 
contraindications to drugs.  
• In 1997, the FDA issued guidelines that described how ads could make 
“adequate provision” for the full disclosure of risks and benefits by referring 
viewers elsewhere, to a toll-free telephone number, concurrent print ad, a web 
site, or a physician. As a result, the pharmaceutical industry greatly increased 
its spending on DTCA, and shifted the majority of its budget from print to 
broadcast media.
• Regulation of DTCA recognizes that prescription drugs differ from other 
consumer products because of the drugs’ inherent risks. Nevertheless, 
commercial speech is given significant protection under U.S. law, leading 
legal scholars to conclude that an outright ban on DTCA would not likely 
pass constitutional muster. The question remains about how to balance these 
constitutional protections with the need to protect the public’s health.
• American television viewers see as many as 16 hours of prescription drug ads 
per year, far exceeding the average time spent with a physician. Pharmaceutical 
manufacturers concentrate DTCA spending on a few brand-name drugs,  
mostly those used to treat chronic conditions with broad and enduring  
potential markets—such as high cholesterol, insomnia, or reduced bone  
density. In 2008, the class of drugs with the greatest DTCA spending was 
treatments for erectile dysfunction.
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Editor’s note:  In 2007, the pharmaceutical industry spent more than $4.9 billion 
on direct-to-consumer advertising (DTCA) of prescription drugs in the U.S. 
Controversy over DTCA has grown since the Food and Drug Administration 
liberalized its regulations in 1997. Proponents claim that such advertising educates 
consumers, promotes patient participation in clinical decisions, and improves 
patient adherence to medication instructions. Opponents argue that such 
advertising is meant to persuade, not educate, and that it promotes inappropriate 
use of prescription drugs, or diverts consumers from better alternatives. This Issue 
Brief summarizes the evidence about the effects of DTCA, and proposes guidelines 
for improving the utility of prescription drug advertising.
Regulation of direct-to-
consumer advertising 
(DTCA) of prescription 
drugs must balance 
constitutional protections 
and public health concerns
Frosch and colleagues reviewed studies published from 1997 to 2009. They judged 
the strength of the evidence for each of the competing claims about DTCA.
• Their conceptual framework centered around the consumer as an active 
participant in medical decision making. Exposure to prescription drug 
advertising can prompt prescription requests, which may be clinically 
appropriate or inappropriate. If the request is inappropriate, and the physician 
cannot or will not correct the patient’s perception, DTCA may lead to 
unnecessary and potentially harmful prescribing. On the other hand, if the 
request is appropriate, DTCA may reduce under prescribing and contribute to 
patient adherence.
• Exposure to ads may also affect consumer perceptions of treatable illnesses 
even if it does not lead to a prescription request. For example, it may prompt 
consumers to seek medical attention for undiagnosed symptoms or remind 
patients about their prescriptions.
Review of evidence focuses 
on how DTCA affects 
clinical care
DTCA provides information 
that is valued by the public, 
but current ads may not 
be an effective education 
vehicle 
DTCA proponents justify the proliferation of ads by citing their educational 
potential. Physicians and patients have been surveyed about their perceptions of 
drug ads, and the content of print and television ads have been studied.
• In surveys of the public, nearly 75% of respondents believe that ads improve 
their understanding of diseases and treatments, and more than 40% report 
using ad information when making medical decisions. 
• In surveys, more than half of physicians agree that DTCA educates patients 
about diseases and treatments. Many physicians, however, believe that DTCA 
both encourages patients to make unwarranted requests for medication, and 
promotes unnecessary fear of side effects.
• Analyses of the content of ads find that most DTCA lacks information 
important to help consumers decide about the benefits and risks of prescription 
drugs. Benefits of drugs are often described in vague terms or through narratives 
that exaggerate the magnitude of benefits. In print ads, most of the content 
exceeds the eighth-grade reading level recommended for the general public.
Studies examining the relationship between DTCA and quality of care have 
focused on whether patients exposed to DTCA have better discussions and 
relationships with their physicians.
• Surveys of physicians and patients suggest that DTCA promotes patients’ 
participation in their medical care and gives patients more confidence to discuss 
health-related concerns. Patients report making better health decisions and 
seeking more information about current and previously diagnosed conditions.
• Evidence concerning the relationship between DTCA and physician-patient 
communication is mixed. Most physicians and patients agree that DTCA can 
prompt important discussions; however, physicians are less likely to endorse 
the positive aspects of DTCA and more likely to worry that DTCA promotes 
longer, unnecessary visits and inappropriate medication requests.
• Limited evidence, including some randomized trials, suggests that DTCA may 
ameliorate under treatment of selected conditions, such as depression.
• DTCA may have a small beneficial effect on patient adherence. Analyses of 
claims data show a small but significant association between DTCA spending 
and duration of treatment with antidepressants and cholesterol-reducing statins.
Effects of DTCA on 
physician-patient 
communication are 
unclear, although it may 
reduce undertreatment 
and improve patient 
adherence in selected 
conditions
Critics of DTCA cite its potential to increase inappropriate prescribing, reflecting 
both cost and safety concerns.
• Physician surveys find that 81% of respondents believe that DTCA promotes 
medication requests, and one-quarter report resulting changes in their 
prescribing habits. In one survey, physicians judged half of DTCA-prompted 
requests to be clinically inappropriate, although 69% of these requests were  
at least partially fulfilled to accommodate patients.
• More rigorous evidence measuring DTCA-prompted prescribing comes from 
claims data and from a randomized experiment using standardized patients 
(actors). The evidence suggests that DTCA-prompted prescription requests 
lead to both appropriate and inappropriate prescribing. Which effect is greater 
remains unclear.
Given the evidence of the risks and benefits of DTCA, Frosch and colleagues 
developed guidelines to maximize the utility of the ads while minimizing their 
clinical risks. In developing guidelines, Frosch and colleagues proposed three goals 
that should guide the content of DTCA. 
• Ads should help identify appropriate candidates for treatment. The majority of 
ads produced to date provide little information that would allow consumers to 
clearly identify whether the advertised product is indicated for them.
• Ads should provide accurate and specific information about the potential 
benefits of the advertised drug instead of the current qualitative and emotion-
laden portrayals that often suggest misleadingly dramatic effects. 
• Ads should provide specific quantitative information about the potential risks 
associated with the drug. Current ads contain a mismatch between visual 
imagery and verbal messages when risk information is presented.
The proposed guidelines distinguish between three target audiences for DTCA: 
those with undiagnosed, asymptomatic conditions (such as hypercholesterolemia); 
those with undiagnosed symptomatic conditions (such as major depression), and 
those with previously diagnosed conditions (such as anemia).  
• Previously diagnosed patients can judge whether they are candidates for 
the drug by the name of the condition alone, but those with undiagnosed 
conditions need more information. Ads targeting undiagnosed, asymptomatic 
patients should also present information on the condition’s prevalence, potential 
clinical consequences, risk factors, and recommended screening tests; those 
targeting undiagnosed patients with symptoms should include information on 
the condition’s prevalence, potential clinical consequences, symptoms, and any 
valid self-administered screening test available.  
• The guidelines call for precise information about absolute risk or symptom 
reduction expected from drug treatment, compared to placebo, lifestyle 
changes, and alternative drugs.  The availability of generic alternatives should  
be noted.
• The guidelines call for risk information to be provided in a final separate block 
of the ad that is narratively and visually distinct from the rest of the ad, without 
background music (to reduce distraction). The pace and density of information 
should be similar to the rest of the ad. The magnitude and frequency of risk 
should be compared to placebo.
DTCA-prompted requests 
increase both appropriate 
and inappropriate 
prescribing
DTCA should better 
identify candidates for 
treatment and provide 
better information on  
drug risks and benefits
Proposed content 
guidelines address 
evidence-based concerns
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In effect, DTCA amounts to an uncontrolled experiment affecting population 
health. This review suggests that DTCA has some benefits, but significant 
risks are evident as well. Regulators and industry representatives alike should 
consider the proposed guidelines for their potential to maximize the utility of 
DTCA.
• The proposed guidelines will likely encounter resistance. Some may argue 
that existing ads are too short to provide all the suggested information. 
However, longer drug ads have been produced and run. Others may argue 
that such information should be communicated by the physician, not the 
ad. This response ignores the time constraints of the typical physician visit, 
which leave little time to address misperceptions induced by DTCA.
• To assess the proposed guidelines’ effect on clinical care and population 
health, they should be tested in a trial period followed by careful evaluation 
of the changes in ad content.
• Significant gaps remain in the evaluation of the effects of current DTCA 
on drug expenditures and population health. Such research would be 
aided by making the actual air dates and times in different media markets 
publicly available.
POLICY IMPLICATIONS
